X

Drug Profile

Epirubicin - Evolve Oncology

Alternative Names: BIO 128

Latest Information Update: 25 Nov 2021

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Gardant Pharmaceuticals
Class Cytostatic antibiotics; Doxorubicins; Small molecules
Mechanism of Action Type II DNA topoisomerase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

No development reported Cancer

Most Recent Events

16 Jul 2016 No recent reports of development identified for phase-I development in Cancer in USA
04 Jan 2007 Gardant Pharmaceuticals has been acquired by Switch Pharma
19 Sep 2005 Phase-I clinical trials in Cancer in USA (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com